← IOVANCE BIOTHERAPEUTICS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.2m |
$164.1m
+13698.99%
|
$263.5m
+60.60%
|
$325.0m
+23.33%
|
|
| Cost of Goods and Services Sold | — | — | — | — | — | — | — | $10.8m |
$124.0m
+1052.91%
|
$173.2m
+39.67%
|
$167.7m
-3.18%
|
|
| Cost of sales | — | — | — | — | — | — | — | $10.8m |
$124.0m
+1052.91%
|
$173.2m
+39.67%
|
$167.7m
-3.18%
|
|
| Non-cash stock-based compensation included in cost of sales | — | — | — | — | — | — | — | — | $8.6m |
$7.3m
-14.82%
|
— | |
| Gross Profit (Calculated) | — | — | — | — | — | — | — | ($9.6m) |
$40.1m
+518.93%
|
$90.3m
+125.37%
|
— | |
| Research and Development Expense | $28.0m | $71.6m | $99.8m | $166.0m | $201.7m | $259.0m | $294.8m | $344.1m | $282.3m | $300.3m | $267.7m | |
| Non-cash stock-based compensation included in research and development | — | — | — | — | — | — | — | $34.9m | $49.3m | $27.0m | — | |
| Non-cash stock-based compensation included in selling, general and administrative | — | — | — | — | — | — | — | $27.7m | $51.8m | $27.3m | — | |
| Amortization of Intangible Assets | — | — | — | — | — | — | — | $9.8m | $21.2m | $23.1m | — | |
| Operating Expenses | $53.6m | $92.9m | $128.3m | $206.9m | $261.9m | $342.7m | $398.9m | $461.7m | $559.3m | $666.9m | $621.1m | |
| Loss from operations | ($53.6m) |
($92.9m)
-73.15%
|
($128.3m)
-38.09%
|
($206.9m)
-61.29%
|
($261.9m)
-26.62%
|
($342.7m)
-30.83%
|
($398.9m)
-16.39%
|
($460.6m)
-15.46%
|
($395.3m)
+14.17%
|
($403.4m)
-2.04%
|
— | |
| Operating Income (Loss) | ($53.6m) |
($92.9m)
-73.15%
|
($128.3m)
-38.09%
|
($206.9m)
-61.29%
|
($261.9m)
-26.62%
|
($342.7m)
-30.83%
|
($398.9m)
-16.39%
|
($460.6m)
-15.46%
|
($395.3m)
+14.17%
|
($403.4m)
-2.04%
|
($296.2m)
+26.57%
|
|
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | — | — | — | ($70k) | $175k | $238k | — | |
| Gain (Loss) Related to Litigation Settlement | — | — | — | $336k | — | — | — | — | — | — | — | |
| Interest and other income, net | $745k | $813k | $4.7m | $9.3m | $2.4m | $451k | $3.0m | $13.0m | $20.3m | $10.3m | — | |
| Net Loss before income taxes | — | — | — | — | — | ($342.3m) | ($395.9m) | ($447.5m) | ($375.0m) | ($393.0m) | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | $342.3m | $395.9m | ($447.5m) | ($375.0m) | ($393.0m) | ($293.8m) | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | ($3.5m) | ($2.8m) | ($2.1m) | ($4.3m) | |
| Net Loss | ($52.9m) | ($92.1m) | ($123.6m) | ($197.6m) | ($259.6m) | ($342.3m) | ($395.9m) | ($444.0m) | ($372.2m) | ($391.0m) | — | |
| Net Income (Loss) Attributable to Parent | ($52.9m) |
($92.1m)
-74.05%
|
($123.6m)
-34.23%
|
($197.6m)
-59.86%
|
($259.6m)
-31.40%
|
($342.3m)
-31.85%
|
($395.9m)
-15.67%
|
($444.0m)
-12.16%
|
($372.2m)
+16.18%
|
($391.0m)
-5.05%
|
($289.5m)
+25.95%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | ($102.3m) | ($92.1m) | ($123.6m) |
($2)
+100.00%
|
($2)
-18.24%
|
($2)
-18.62%
|
($2)
-11.66%
|
($2)
+24.10%
|
($1)
+32.28%
|
($1)
+14.84%
|
($289.5m)
-26561192560.55%
|
|
| Earnings Per Share, Basic | ($102.3m) | ($92.1m) | ($123.6m) | ($1.59) | ($1.88) | ($2.23) | ($2.49) | ($1.89) | ($1.28) | ($1.09) | ($0.69) | |
| Earnings Per Share, Diluted | ($1.85) | ($1.41) | ($1.27) | ($1.59) | ($1.88) | ($2.23) | ($2.49) | ($1.89) | ($1.28) | ($1.09) | ($0.69) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | 124k | 138k | 153k | 159k | 235k | 290k | 357k | 410.2m | |
| Weighted Average Shares of Common Stock Outstanding, Basic (in shares) | — | — | — | 124k | 138k | 153k | 159k | 235k | 290k | 357k | 410.2m | |
| Weighted Average Shares of Common Stock Outstanding, Diluted (in shares) | — | — | — | 124k | 138k | 153k | 159k | 235k | 290k | 357k | 410.2m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | 124k | 138k | 153k | 159k | 235k | 290k | 357k | 410.2m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | $53.6m | $92.9m | $128.3m | $206.9m | $261.9m | $342.7m | $398.9m | $461.7m | $559.3m | $666.9m | — | |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | $18.9m | $12.0m | $20k | $24.3m | $40.9m | $69.8m | $84.0m | $62.6m | $109.6m | $61.6m | — | |
| Depreciation and amortization | — | — | — | — | — | — | — | $21.4m | $37.6m | $35.9m | $36.6m | |
| Share-based Compensation | — | — | — | — | — | — | — | $62.6m | $109.6m | $61.6m | — |